Merck’s KEYTRUDA–Padcev combo delivers survival gains in Phase 3 bladder cancer trial

Lupin secures SBTi validation for emission reduction targets

Bristol Myers Squibb launches AI-powered ‘Mosaic’ hub in Mumbai

India plays a critical role in Bristol Myers Squibb’s global strategy

Merck KGaA launches ChemiSphere App to digitize lab workflows

The ChemiSphere app exemplifies how M-Trust technology transforms workflows into seamless digital experiences

Ascletis Pharma reports positive Phase I results for oral IL-17 inhibitor

The randomized, double-blind, placebo-controlled single ascending dose (SAD) study evaluated safety, tolerability, pharmacokinetics, and target engagement in 46 healthy participants

FDA nod to first oral single-dose treatment for gonorrhea

The approval of Nuzolvence (zoliflodacin) follows a collaborative development effort with the Global Antibiotic Research and Development Partnership

Caplin Point Laboratories’ injectables facility completes INVIMA audit successfully

This is also an important milestone in our product strategy for our expansion into the larger Latin American market

Emcure Pharmaceuticals appoints Barnona Basu as Director – Marketing (India)

Suven Life Sciences achieved 100% patient enrolment in Phase-2b clinical trial of Ropanicant for MDO

The Phase-2b study is a randomized, double-blind, placebo-controlled trial that will enroll approximately 195 patients across 35 sites in the USA

New oral SERD from Roche delivers significant survival edge in early breast cancer

At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival